A detailed history of Janus Henderson Group PLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 71,743 shares of RARE stock, worth $3.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
71,743
Previous 32,151 123.14%
Holding current value
$3.61 Million
Previous $1.5 Million 96.4%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$37.42 - $51.61 $1.48 Million - $2.04 Million
39,592 Added 123.14%
71,743 $2.95 Million
Q1 2024

May 15, 2024

BUY
$43.02 - $53.69 $559 - $697
13 Added 0.04%
32,151 $1.5 Million
Q3 2023

Nov 14, 2023

BUY
$34.92 - $46.66 $279 - $373
8 Added 0.02%
32,138 $1.15 Million
Q2 2023

Aug 14, 2023

SELL
$37.35 - $52.15 $1,307 - $1,825
-35 Reduced 0.11%
32,130 $1.48 Million
Q1 2023

May 15, 2023

BUY
$36.99 - $48.71 $711,465 - $936,888
19,234 Added 148.74%
32,165 $1.29 Million
Q4 2022

Feb 14, 2023

BUY
$33.72 - $46.33 $33 - $46
1 Added 0.01%
12,931 $599,000
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $159 - $264
4 Added 0.03%
12,930 $535,000
Q2 2022

Aug 15, 2022

BUY
$45.8 - $85.4 $458 - $854
10 Added 0.08%
12,926 $772,000
Q1 2022

May 16, 2022

SELL
$62.2 - $84.4 $1.48 Million - $2.01 Million
-23,772 Reduced 64.8%
12,916 $938,000
Q4 2021

Feb 14, 2022

SELL
$73.71 - $87.86 $4.56 Million - $5.43 Million
-61,841 Reduced 62.76%
36,688 $3.09 Million
Q3 2021

Nov 16, 2021

BUY
$77.92 - $102.4 $7.68 Million - $10.1 Million
98,529 New
98,529 $8.89 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.53B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.